Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.
Ameratunga M, Chénard-Poirier M, Moreno Candilejo I, Pedregal M, Lui A, Dolling D, Aversa C, Ingles Garces A, Ang JE, Banerji U, Kaye S, Gan H, Doger B, Moreno V, de Bono J, Lopez J. Ameratunga M, et al. Among authors: ang je. Eur J Cancer. 2018 Jan;89:56-63. doi: 10.1016/j.ejca.2017.11.012. Epub 2017 Dec 8. Eur J Cancer. 2018. PMID: 29227818 Clinical Trial.
Ovarian cancer: can we reverse drug resistance?
Tan DS, Ang JE, Kaye SB. Tan DS, et al. Among authors: ang je. Adv Exp Med Biol. 2008;622:153-67. doi: 10.1007/978-0-387-68969-2_13. Adv Exp Med Biol. 2008. PMID: 18546626 Review. No abstract available.
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience.
Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, Reid AH, A'Hern R, Fong PC, Oomen NB, Molife R, Dearnaley D, Parker C, Terstappen LW, de Bono JS. Olmos D, et al. Among authors: ang je. Ann Oncol. 2009 Jan;20(1):27-33. doi: 10.1093/annonc/mdn544. Epub 2008 Aug 11. Ann Oncol. 2009. PMID: 18695026 Free article.
A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma.
Ang JE, Shah RN, Everard M, Keyzor C, Coombes I, Jenkins A, Thomas K, A'Hern R, Jones RL, Blake P, Gabra H, Hall G, Gore ME, Kaye SB. Ang JE, et al. Ann Oncol. 2009 Nov;20(11):1787-93. doi: 10.1093/annonc/mdp193. Epub 2009 Jun 19. Ann Oncol. 2009. PMID: 19542250 Free article. Clinical Trial.
47 results